Skip to contents

Paul B. Yu, MD, PhD
Associate Physician, Brigham and Women's Hospital
Associate Professor of Medicine, Harvard Medical School

Brigham and Women's Hospital
Department of Medicine
75 Francis Street
Boston, MA 02115

Research Location: Thorn Research Building

Edit Profile

Research Narrative:

Dr. Yu’s laboratory is focused on understanding how signaling via the bone morphogenetic protein (BMP), activin, growth and differentiation factor (GDF), and TGF-beta signaling pathways regulate the consequences of injury and inflammation in cardiovascular and musculoskeletal biology. These themes have been explored in models of pulmonary arterial hypertension, vascular and valvular calcification, anemia of inflammation, heterotopic ossification, and fibrodysplasia ossificans progressiva, with a goal of translating mechanistic insights into novel therapeutics.

Mass General Hospital, 2005, Cardiovasc Medicine
UCSF, 2001, Internal Med
Duke University, 2000, Ph.D.
Duke University, 1999, MD
Stanford University, 1994, B.S., A.B.

Courses Taught:
2012-15, Harvard Medical School, Pursuing Inquiry in Medicine

Publications (Pulled from Harvard Catalyst Profiles):

1. Wertheim BM, Lin YD, Zhang YY, Samokhin AO, Alba GA, Arons E, Yu PB, Maron BA. Isolating pulmonary microvascular endothelial cells ex vivo: Implications for pulmonary arterial hypertension, and a caution on the use of commercial biomaterials. PLoS One. 2019; 14(2):e0211909.

2. Yang P, Yu PB. In Search of the Second Hit in Pulmonary Arterial Hypertension. Circ Res. 2019 Jan 04; 124(1):6-8.

3. Graham BB, Yu PB. Finding the Target: In Silico and Genetic Screening for Mechanistically Novel Drugs in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2019 Jan 01; 199(1):9-11.

4. Dinter T, Bocobo GA, Yu PB. Pharmacologic Strategies for Assaying BMP Signaling Function. Methods Mol Biol. 2019; 1891:221-233.

5. Nikolic I, Yung LM, Yang P, Malhotra R, Paskin-Flerlage SD, Dinter T, Bocobo GA, Tumelty KE, Faugno AJ, Troncone L, McNeil ME, Huang X, Coser KR, Lai CSC, Upton PD, Goumans MJ, Zamanian RT, Elliott CG, Lee A, Zheng W, Berasi SP, Huard C, Morrell NW, Chung RT, Channick RW, Roberts KE, Yu PB. Bone Morphogenetic Protein 9 is a Mechanistic Biomarker of Portopulmonary Hypertension. Am J Respir Crit Care Med. 2018 Oct 12.

6. Jiang JK, Huang X, Shamim K, Patel PR, Lee A, Wang AQ, Nguyen K, Tawa G, Cuny GD, Yu PB, Zheng W, Xu X, Sanderson P, Huang W. Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors. Bioorg Med Chem Lett. 2018 Nov 01; 28(20):3356-3362.

7. Yung LM, Yu PB. Room With a View. Circ Cardiovasc Imaging. 2018 Aug; 11(8):e008148.

8. Brittain EL, Thennapan T, Maron BA, Chan SY, Austin ED, Spiekerkoetter E, Bogaard HJ, Guignabert C, Paulin R, Machado RF, Yu PB. Update in Pulmonary Vascular Disease 2016 and 2017. Am J Respir Crit Care Med. 2018 Jul 01; 198(1):13-23.

9. Samokhin AO, Stephens T, Wertheim BM, Wang RS, Vargas SO, Yung LM, Cao M, Brown M, Arons E, Dieffenbach PB, Fewell JG, Matar M, Bowman FP, Haley KJ, Alba GA, Marino SM, Kumar R, Rosas IO, Waxman AB, Oldham WM, Khanna D, Graham BB, Seo S, Gladyshev VN, Yu PB, Fredenburgh LE, Loscalzo J, Leopold JA, Maron BA. NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension. Sci Transl Med. 2018 Jun 13; 10(445).

10. Agarwal S, Spiekerkoetter E, Austin ED, de Jesus Perez V, Dezfulian C, Maron BA, Ryan JJ, Starks MA, Yu PB, Bonnet S, Perman SM. Career Development of Young Physician-Scientists in the Cardiovascular Sciences: Perspective and Advice From the Early Career Committee of the Cardiopulmonary, Critical Care, and Resuscitation Council of the American Heart Association. Circ Res. 2018 May 11; 122(10):1330-1333.